Avantor, Inc. (AVTR) FinancialsAVTRAvantor, Inc.

Avantor, Inc. (AVTR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Proprietary materials & consumables, accounting for 52.0% of total sales, equivalent to $880.40M. Another important revenue stream is Third party materials & consumables. Understanding this composition is critical for investors evaluating how AVTR navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Avantor, Inc. maintains a gross margin of 31.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.20%, while the net margin is 2.25%. These profitability ratios, combined with a Return on Equity (ROE) of -9.70%, provide a clear picture of how effectively AVTR converts its operational activities into shareholder value.

In the context of the broader market, AVTR competes directly with industry leaders such as PODD and BIO. With a market capitalization of $9.88B, it holds a significant position in the sector. When comparing efficiency, AVTR's gross margin of 31.73% stands against PODD's 70.18% and BIO's 53.12%. Such benchmarking helps identify whether Avantor, Inc. is trading at a premium or discount relative to its financial performance.

Avantor's Q2 2026 net sales were $1.69 billion, reflecting a 0.5% year-over-year increase, and the company raised its adjusted EPS guidance to $0.80-$0.83, indicating positive growth expectations.